Nautilus Biotechnology, Inc. Share Price & Technical Analysis
NAUT · $2.54 (0.00%)
Healthcare / Biotechnology
$2.54
0.00%
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, …
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-7% return in May, 5% avg return in past 3 year May month.
60% return in 2026, 21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | 26% | 70% | -33% | -7% | – | – | – | – | – | – | – | 60% |
| 25 | 0% | -24% | -31% | -22% | 0% | -12% | 14% | -12% | 14% | 63% | 57% | -9% | 38% |
| 24 | -7% | -4% | 7% | -14% | 4% | -15% | 17% | -4% | 8% | -10% | -19% | -23% | -58% |
| 23 | 11% | 5% | 33% | -7% | 12% | 39% | -17% | -3% | 0% | -16% | 12% | 15% | 84% |
| 22 | -24% | -2% | 5% | 9% | -20% | -27% | 7% | -24% | -5% | 14% | -25% | 0% | -91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$368.53M
P/E ratio
—
52W high
$4.31
52W low
$0.62
Volume
3,63,063
Beta
0.75
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Nautilus Biotechnology, Inc. share price today?
- Nautilus Biotechnology, Inc. (NAUT) last traded around $2.54 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NAUT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NAUT. Download the app for real-time alerts.
- How can I analyze Nautilus Biotechnology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.